TY - JOUR
T1 - Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease
AU - Michaud, Kaleb
AU - Berglind, Niklas
AU - Franzén, Stefan
AU - Frisell, Thomas
AU - Garwood, Christopher
AU - Greenberg, Jeffrey D.
AU - Ho, Meilien
AU - Holmqvist, Marie
AU - Horne, Laura
AU - Inoue, Eisuke
AU - Nyberg, Fredrik
AU - Pappas, Dimitrios A.
AU - Reed, George
AU - Symmons, Deborah
AU - Tanaka, Eiichi
AU - Tran, Trung N.
AU - Verstappen, Suzanne M.M.
AU - Wesby-Van Swaay, Eveline
AU - Yamanaka, Hisashi
AU - Askling, Johan
N1 - Publisher Copyright:
© 2016 Published by the BMJ Publishing Group Limited.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Background: We implemented a novel method for providing contextual adverse event rates for a randomised controlled trial (RCT) programme through coordinated analyses of five RA registries, focusing here on cardiovascular disease (CVD) and mortality. Methods: Each participating registry (Consortium of Rheumatology Researchers of North America (CORRONA) (USA), Swedish Rheumatology Quality of Care Register (SRR) (Sweden), Norfolk Arthritis Register (NOAR) (UK), CORRONA International (East Europe, Latin America, India) and Institute of Rheumatology, Rheumatoid Arthritis (IORRA) (Japan)) defined a main cohort from January 2000 onwards. To address comparability and potential bias, we harmonised event definitions and defined several subcohorts for sensitivity analyses based on disease activity, treatment, calendar time, duration of follow-up and RCT exclusions. Rates were standardised for age, sex and, in one sensitivity analysis, also HAQ. Results: The combined registry cohorts included 57 251 patients with RA (234 089 person-years) - 24.5% men, mean (SD) baseline age 58.2 (13.8) and RA duration 8.2 (11.7) years. Standardised registry mortality rates (per 100 person-years) varied from 0.42 (CORRONA) to 0.80 (NOAR), with 0.60 for RCT patients. Myocardial infarction and major adverse cardiovascular events (MACE) rates ranged from 0.09 and 0.31 (IORRA) to 0.39 and 0.77 (SRR), with RCT rates intermediate (0.18 and 0.42), respectively. Additional subcohort analyses showed small and mostly consistent changes across registries, retaining reasonable consistency in rates across the Western registries. Additional standardisation for HAQ returned higher mortality and MACE registry rates. Conclusions: This coordinated approach to contextualising RA RCT safety data demonstrated reasonable differences and consistency in rates for mortality and CVD across registries, and comparable RCT rates, and may serve as a model method to supplement clinical trial analyses for drug development programmes.
AB - Background: We implemented a novel method for providing contextual adverse event rates for a randomised controlled trial (RCT) programme through coordinated analyses of five RA registries, focusing here on cardiovascular disease (CVD) and mortality. Methods: Each participating registry (Consortium of Rheumatology Researchers of North America (CORRONA) (USA), Swedish Rheumatology Quality of Care Register (SRR) (Sweden), Norfolk Arthritis Register (NOAR) (UK), CORRONA International (East Europe, Latin America, India) and Institute of Rheumatology, Rheumatoid Arthritis (IORRA) (Japan)) defined a main cohort from January 2000 onwards. To address comparability and potential bias, we harmonised event definitions and defined several subcohorts for sensitivity analyses based on disease activity, treatment, calendar time, duration of follow-up and RCT exclusions. Rates were standardised for age, sex and, in one sensitivity analysis, also HAQ. Results: The combined registry cohorts included 57 251 patients with RA (234 089 person-years) - 24.5% men, mean (SD) baseline age 58.2 (13.8) and RA duration 8.2 (11.7) years. Standardised registry mortality rates (per 100 person-years) varied from 0.42 (CORRONA) to 0.80 (NOAR), with 0.60 for RCT patients. Myocardial infarction and major adverse cardiovascular events (MACE) rates ranged from 0.09 and 0.31 (IORRA) to 0.39 and 0.77 (SRR), with RCT rates intermediate (0.18 and 0.42), respectively. Additional subcohort analyses showed small and mostly consistent changes across registries, retaining reasonable consistency in rates across the Western registries. Additional standardisation for HAQ returned higher mortality and MACE registry rates. Conclusions: This coordinated approach to contextualising RA RCT safety data demonstrated reasonable differences and consistency in rates for mortality and CVD across registries, and comparable RCT rates, and may serve as a model method to supplement clinical trial analyses for drug development programmes.
KW - Cardiovascular Disease
KW - Epidemiology
KW - Outcomes research
KW - Rheumatoid Arthritis
UR - http://www.scopus.com/inward/record.url?scp=84958092529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958092529&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2015-208698
DO - 10.1136/annrheumdis-2015-208698
M3 - Article
C2 - 26857699
AN - SCOPUS:84958092529
SN - 0003-4967
VL - 75
SP - 1797
EP - 1805
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 10
ER -